Adoptive transfer of pulsed DCs into tumor-bearing mice in combination with pan-PI3K inhibition resulted in a significant increase in anti-tumoral T-cell response, decrease in tumor growth and prolonged overall survival, demonstrating the potential of PI3K inhibitors for the development of tumor DC-based vaccines. This evidence concerns the gene PIK3CD and neoplasm.